Recent publications
Article
Mehanna, H, Gaunt, P, Kong, A, Hartley, A, Sanghera, P, Forster, M, Sen, M, Paleri, V, Fong, C, Geropantas, D, Srinivasan, D, Garikipati, S, Moleron, R, Casswell, G, Aynsley, E, Ward, A, O'Toole, L, Mirza, A, Firth, C, Humphreys, I, Fulton-Lieuw, T & Nankivell, P 2024, 'CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer', Trials, vol. 25, 50. https://doi.org/10.1186/s13063-023-07881-1
Patel, A, Brock, K, Slade, D, Gaunt, C, Kong, A, Mehanna, H, Billingham, L & Gaunt, P 2024, 'Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial', BMC Medical Research Methodology, vol. 24, no. 1, 11. https://doi.org/10.1186/s12874-024-02142-4
PETNECK2 Research Team, Nankivell, P, Gaunt, P, Gaunt, C, Sissons, J, Liaskou, E, Jefferson, Y, Fulton-Lieuw, T, Mittal, S & Mehanna, H 2024, 'PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial', BMC Cancer, vol. 24, no. 1, 823. https://doi.org/10.1186/s12885-024-12470-9
Simões, R, Gulliford, S, Seddon, B, Dehbi, H-M, Robinson, M, Forsyth, S, Hughes, A, Gaunt, P, Nguyen, T-G, Elston, S, Mohammed, K, Zaidi, S, Miles, E, Hoskin, P, Harrington, K & Miah, A 2024, 'Predicting radiotherapy response, Toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose–volume constraints development: a study protocol', BMJ open, vol. 14, no. 8, e083617. https://doi.org/10.1136/bmjopen-2023-083617
Woll, PJ, Gaunt, P, Gaskell, C, Young, R, Benson, C, Judson, IR, Seddon, BM, Marples, M, Ali, N, Strauss, SJ, Lee, A, Kaur, B, Billingham, L & David, H 2023, 'Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata', British Journal of Cancer, vol. 129, no. 9, pp. 1490-1499. https://doi.org/10.1038/s41416-023-02416-6
Forker, LJ, Bibby, B, Yang, L, Lane, B, Irlam, J, Mistry, H, Khan, M, Valentine, H, Wylie, J, Shenjere, P, Leahy, M, Gaunt, P, Billingham, L, Seddon, BM, Grimer, R, Robinson, M, Choudhury, A & West, C 2023, 'Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma', British Journal of Cancer. https://doi.org/10.1038/s41416-023-02265-3
Homer, V, Yap, C, Bond, S, Holmes, J, Stocken, D, Walker, K, Robinson, EJ, Wheeler, G, Brown, S, Hinsley, S, Schipper, M, Weir, CJ, Rantell, K, Prior, T, Yu, L-M, Kirkpatrick, J, Bedding, A, Gamble, C & Gaunt, P 2022, 'Early phase clinical trials extension to guidelines for the content of statistical analysis plans', BMJ, vol. 376, e068177. https://doi.org/10.1136/bmj-2021-068177
Woll, P, Gaunt, P, Danson, S, Steele, N, Ahmed, S, Mulatero, C, Shah, R, Bhosle, J, Hodgkinson, E, Watkins, B & Billingham, L 2022, 'Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): a randomised, double-blind, placebo-controlled phase II trial', Lung Cancer, vol. 171, pp. 26-33. https://doi.org/10.1016/j.lungcan.2022.07.007
Hasan, Z-U, Ahmed, I, Matin, RN, Homer, V, Lear, JT, Ismail, F, Whitmarsh, T, Green, AC, Thomson, J, Milligan, A, Hogan, S, Van-de-Velde, V, Mitchell-Worsford, L, Kentley, J, Bowden, S, Gaunt, P, Wheatley, K, Proby, CM & Harwood, CA 2022, 'Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)', British Journal of Dermatology, vol. 187, no. 3, pp. 324-337. https://doi.org/10.1111/bjd.20974
Meade, S, Gaunt, P, Hartley, A, Robinson, M, Cashmore, J, Wagstaff, L, Babrah, J, Bowden, SJ, Mehanna, H & Sanghera, P 2018, 'Feasibility of Dose-escalated Hypofractionated Chemoradiation in Human Papilloma Virus-negative or Smoking-associated Oropharyngeal Cancer', Clinical Oncology. https://doi.org/10.1016/j.clon.2018.01.015
Forker, L, Gaunt, P, Sioletic, S, Shenjere, P, Potter, R, Roberts, D, Irlam, J, Valentine, H, Hughes, A, Billingham, L, Grimer, R, Seddon, B, Choudhury, A, Robinson, M, West, CML & David, H 2018, 'The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma', British Journal of Cancer, vol. 118, no. 5, pp. 698-704. https://doi.org/10.1038/bjc.2017.430
Ferry, D, Billingham, L, Jarrett, H, Dunlop, D, Woll, PJ, Nicolson, M, Shah, R, Thompson, J, Spicer, J, Muthukumar, D, Skailes, G, Leonard, P, Chetiyawardana, AD, Wells, P, Lewanski, C, Crosse, B, Hill, M, Gaunt, P & O'Byrne, K 2017, 'Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial', European Journal of Cancer, vol. 83, pp. 302-312. https://doi.org/10.1016/j.ejca.2017.05.037
Comment/debate
PETNECK2 Research Team, Nankivell, P, Gaunt, P, Gaunt, C, Sissons, J, Liaskou, E, Jefferson, Y, Fulton-Lieuw, T, Mittal, S & Mehanna, H 2024, 'Correction: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial', BMC Cancer, vol. 24, no. 1, 861. https://doi.org/10.1186/s12885-024-12639-2
Letter
Wheatley, K, Wilson, JS, Gaunt, P & Marsden, JR 2017, 'Reply to response to Wheatley et al., “Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation” Cancer Treatment Reviews April 2016;45:76', Cancer Treatment Reviews, vol. 55, pp. 225-229. https://doi.org/10.1016/j.ctrv.2016.07.002
Armstrong, MJ, Gaunt, P & Newsome, PN 2016, 'Identifying patients with nonalcoholic steatohepatitis that are nonresponders to therapy', Hepatology. https://doi.org/10.1002/hep.28672
View all publications in research portal